NCT05477004
Observational Study of Ketamine Infusions for the Treatment of Chronic Pain
Enrolling by Invitation
Not specifiedAges 18+ObservationalTheresa LiiInvestigator-initiated
~100 participants
Updated 2025-12-19 on ClinicalTrials.gov
What's tested:Ketamine
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline Patient Global Impression of Change (PGIC) in overall status; measured with PGIC Scale
Measured over 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months (or up to the time of their next ketamine infusion)
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Theresa Lii, MD · PRINCIPAL_INVESTIGATOR · Stanford University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Has been seen at Stanford's Pain Management Center for a doctor's visit at least once.
Is scheduled to undergo at least 1 ketamine infusion for the treatment of any chronic pain condition.
Have a valid email address and consents to receiving surveys by email.
Able to read, understand, and respond to English-language surveys on an electronic device such as a cell phone, tablet, or computer.
Able to read, understand, and provide written, dated informed consent.
Exclusion
Has their ketamine infusion cancelled, which may occur before or after consenting to this study.
What this trial measures
- Change from baseline Patient Global Impression of Change (PGIC) in overall status; measured with PGIC Scale1 week, 2 weeks, 1 month, 2 months, 3 months, 6 months, 12 months (or up to the time of their next ketamine infusion)
The PGIC Scale is a single-question 7-point Likert scale ranging from "Very much improved" to "Very much worse."